Asset Details
Do you wish to reserve the book?
Pharmacokinetics of Sulfadoxine-Pyrimethamine in HIV-Infected and Uninfected Pregnant Women in Western Kenya
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pharmacokinetics of Sulfadoxine-Pyrimethamine in HIV-Infected and Uninfected Pregnant Women in Western Kenya
Do you wish to request the book?
Pharmacokinetics of Sulfadoxine-Pyrimethamine in HIV-Infected and Uninfected Pregnant Women in Western Kenya
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pharmacokinetics of Sulfadoxine-Pyrimethamine in HIV-Infected and Uninfected Pregnant Women in Western Kenya
2007
Overview
Background. Sulfadoxine-pyrimethamine (SP) is among the most commonly used antimalarial drugs during pregnancy, yet the pharmacokinetics of SP are unknown in pregnant women. HIV-infected (HIV+) women require more frequent doses of intermittent preventive therapy with SP than do HIV-uninfected (HIV-) women. We investigated whether this reflects their impaired immunity or an HIV-associated alteration in the disposition of SP. Methods. Seventeen pregnant HIV- women and 16 pregnant HIV+ women received a dose of 1500 mg of sulfadoxine and 75 mg of pyrimethamine. Five HIV- and 6 HIV+ postpartum women returned 2–3 months after delivery for another dose. The pharmacokinetics of sulfadoxine and pyrimethamine were compared between these groups. Results. HIV status did not affect the area under the curve (AUC0→∞) or the half-lives of sulfadoxine or pyrimethamine in prepartum or postpartum women, although partum status did have a significant affect on sulfadoxine pharmacokinetics. Among prepartum women, the median half-life for sulfadoxine was significantly shorter than that observed in postpartum women (148 vs 256 h; P < .001), and the median AUC0→∞ was ∼40% lower (22,816 vs 40,106 μg/mL/h, P < .001). HIV status and partum status did not show any significant influence on pyrimethamine pharmacokinetics. Conclusion. Pregnancy significantly modifies the disposition of SP, whereas HIV status has little influence on pharmacokinetic parameters in pregnant women.
Publisher
The University of Chicago Press,University of Chicago Press
Subject
/ Adult
/ Antimalarials - pharmacokinetics
/ Antimalarials - therapeutic use
/ Blood
/ Dosage
/ Female
/ HIV
/ HIV/AIDS
/ Human immunodeficiency virus
/ Humans
/ Kenya
/ Malaria
/ Malaria - prevention & control
/ Pregnancy Complications, Parasitic - prevention & control
/ Pyrimethamine - pharmacokinetics
/ Pyrimethamine - therapeutic use
/ Sulfadoxine - pharmacokinetics
/ Sulfadoxine - therapeutic use
/ Women
